®®®® SIIA Público

Título del libro: Immunotherapy In Resistant Cancer: From The Lab Bench Work To Its Clinical Perspectives
Título del capítulo: The IgM as a tool for recognition of early tumoral antigens

Autores UNAM:
PEDRO ULISES GUADALUPE OSTOA SALOMA;
Autores externos:

Idioma:

Año de publicación:
2020
Palabras clave:

2D immunoblot; Breast cancer; Early diagnosis; Natural IgM; Tumor antigens


Resumen:

Breast cancer is the most common cancer in women in the world, therefore, research aimed at finding ways of early detection maintains great importance in this disease. Tools that contribute to the recognition of cancer warning signs can lead to early diagnosis in a healthy population to identify people with the disease at an initial stage when symptoms are not yet apparent. Early detection will increase the survival rate of patients and, therefore, an effective treatment option to fight the disease. The innate immune system recognizes and eliminates cancer cells. This chapter describes the advantages of IgM, in their innate form called natural IgM, to identify tumor antigens in order to find a candidate to be considered as an early diagnostic tool for breast cancer. Most research on biomarkers in breast cancer has focused on the use of IgG, taking advantage of its properties even as a therapeutic tool. However, there is currently no diagnostic method for early detection of breast cancer. The chapter will also try to answer the following questions: In a precancerous condition, is it possible to identify and differentiate the antigens recognized by both IgM and IgG and determine which immunoglobulin is best for identifying antigens in early stages? How would it be the recognition of IgM towards tumor antigens in the middle of a genetic background associated with resistance and/or susceptibility? By measuring the pattern of IgM recognition of tumor antigens, would it be possible to differentiate which individuals are more susceptible and which less? And therefore, by means of IgM, antigens associated with susceptibility and/or resistance to breast cancer could be recognized. © 2021 Elsevier Inc. All rights reserved.


Entidades citadas de la UNAM: